Medical Condition News

RSS

Heart patients living with children exercise less: Study

A study conducted at the Montreal Heart Institute (MHI) has shown unexpectedly that living with children is linked to a reduction in physical activity. Carried out with 756 participants and led by Dr. Simon L. Bacon, Associate Researcher at the MHI and Professor at Concordia University, the study assessed the impact of social networks on exercise, revealing that people with heart disease who live with children exercise less than those people who do not live with children.

20 Jul 2010

ASTRO accepts 4 abstracts on Stereotactic Body Radiation Therapy for NSCLC

The American Society for Radiation Oncology (ASTRO) has accepted four abstracts from users of Elekta Stereotactic Body Radiation Therapy (SBRT) technology on the use of SBRT to treat non-small cell lung cancer (NSCLC). The clinicians will present their findings during presentations at ASTRO's 52nd Annual Meeting (October 31 - November 4) at the San Diego Convention Center.

From Elekta 20 Jul 2010

New report on neuropsychiatric link with ophthalmologic investigations

Regardless of culture, language, era, or individual artist, the arts consistently depict depression using darkness. Scientific findings now lend empirical support to this representation of depression that everything looks gray when you feel blue.

20 Jul 2010

Tool kit for non-experts to measure ADA compliance

Twenty years after the signing of the Americans with Disabilities Act, there is finally a "tool kit" for non-experts to measure whether public facilities are in compliance.This is designed to meet the needs of anyone who is reasonably intelligent but not necessarily a techie,explains Denis Anson, director of research for the Assistive Technology Research Institute (ATRI) at Misericordia University in Dallas, Pennsylvania, and the kit's developer.

20 Jul 2010

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).

20 Jul 2010

Athletes who undergo tissue transplant surgery for knee damage can return to sports: Study

Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.

20 Jul 2010

Study seeks patients with cancer of oropharynx to participate in Phase I clinical trial of SRS

The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth)) to participate in a Phase I clinical trial.

20 Jul 2010

Traumatic brain injuries during war increase risk of epilepsy even decades later

Soldiers who receive traumatic brain injuries during war may be at a higher risk of epilepsy even decades after the brain injury occurred. The new research is published in the July 20, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

20 Jul 2010

New approach to understand different cancer subtypes

An international team led by St. Jude Children's Research Hospital scientists finds unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor

20 Jul 2010

Dyax launches newly enhanced product website featuring comprehensive financial assistance program

Dyax Corp. today announced that it has launched its newly enhanced product website, www.KALBITOR.com, featuring its comprehensive financial assistance program. KALBITOR (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.

20 Jul 2010

Jinfiniti Biosciences moves from clinical studies to developing biomarkers

A new biotech company has grown out of laboratory and clinical studies at the Medical College of Georgia with the goal of improving the diagnosis and treatment of diabetes and cancer.

20 Jul 2010

New report compares efficacy of Plavix, Effient in treating patients with ACS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of acute coronary syndrome, 56 percent of surveyed interventional cardiologists who prescribe Bristol-Myers Squibb/Sanofi-Aventis' Plavix in high doses, consider it to be comparable in efficacy to Daiichi Sankyo/Eli Lilly's recently-launched Effient.

20 Jul 2010

Researchers use bioelectric signals of brain to detect neurodegenerative diseases

A group of researchers from Universidad Carlos III de Madrid has presented a new algorithm that uses a new method to analyse the information obtained from electroencephalograms to detect neurodegenerative diseases, such as epilepsy, using the bioelectric signals of the brain.

20 Jul 2010

Obesity, chronic pain linked to family history, mood disorders: Study

Though it is well known obese individuals have a high incidence of persistent pain problems, a new study in The Journal of Pain, published by the American Pain Society, reports that comorbid obesity and pain also are linked to family history and mood disorders.

20 Jul 2010

Novo Nordisk completes patient enrollment in A1chieve study for type 2 diabetes management

Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.

From Novo Nordisk 20 Jul 2010

Scientists find major shortcomings in assessing CVD risk in HIV patients

At the same time that medical science has nearly eliminated AIDS deaths in patients treated for human immunodeficiency virus, two international meetings of HIV/AIDS scientists and patient advocates find major shortcomings in the design and analysis of studies used to assess cardiovascular disease risk in people with HIV with significant implications for improving medical care.

20 Jul 2010

MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD

MDMA (-3,4-methylenedioxymethamphetamine, also known as Ecstasy), may one day offer hope for individuals with posttraumatic stress disorder (PTSD), even people for whom other treatments have failed. Clinical trial results out today in the Journal of Psychopharmacology, published by SAGE, suggests that MDMA can be administered to subjects with PTSD without evidence of harm and could offer sufferers a vital window with reduced fear responses where psychotherapy can take effect.

20 Jul 2010

LCA opens registration for next Team Lung Love event

Today, Lung Cancer Alliance (LCA) opened registration for the next Team Lung Love event. Members of Team Lung Love can participate in the Philadelphia Marathon, Half-Marathon and 8K this November. Team Lung Love is LCA's endurance sports training program is focused exclusively on raising awareness and support for lung cancer.

20 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

Medical Condition News

Heart patients living with children exercise less: Study

ASTRO accepts 4 abstracts on Stereotactic Body Radiation Therapy for NSCLC

New report on neuropsychiatric link with ophthalmologic investigations

Tool kit for non-experts to measure ADA compliance

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

Athletes who undergo tissue transplant surgery for knee damage can return to sports: Study

Study seeks patients with cancer of oropharynx to participate in Phase I clinical trial of SRS

Traumatic brain injuries during war increase risk of epilepsy even decades later

New approach to understand different cancer subtypes

Dyax launches newly enhanced product website featuring comprehensive financial assistance program

Jinfiniti Biosciences moves from clinical studies to developing biomarkers

New report compares efficacy of Plavix, Effient in treating patients with ACS

Researchers use bioelectric signals of brain to detect neurodegenerative diseases

Obesity, chronic pain linked to family history, mood disorders: Study

Novo Nordisk completes patient enrollment in A1chieve study for type 2 diabetes management

Scientists find major shortcomings in assessing CVD risk in HIV patients

MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD

LCA opens registration for next Team Lung Love event

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

CytRx updates on progress in clinical development of bafetinib in three oncology indications

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News